On Jul. 14, 2015, Benaroya Research Institute at Virginia Mason (BRI) announced that Carla J. Greenbaum, MD, had been named chair of Type 1 Diabetes TrialNet, the National Institutes of Health (NIH) funded clinical trial network for type 1 diabetes prevention and early treatment. Dr. Greenbaum is Director of the Diabetes Research Program and Clinical Research Center at Benaroya Research Institute at Virginia Mason (BRI) in Seattle. She succeeds Jay Skyler, MD, Professor of Medicine, Pediatrics and Psychology at the University of Miami Miller School of Medicine. In addition to the NIH, TrialNet is supported by JDRF and the American Diabetes Association.

Type 1 Diabetes TrialNet is an international consortium dedicated to finding ways to prevent, delay and slow progression of the disease. TrialNet is conducting clinical trials with researchers from 17 clinical centers in the United States and six internationally. An additional 200 affiliated research sites are participating in the TrialNet network. Studies are available for people newly diagnosed with type 1 diabetes, as well as for relatives of people with type 1 diabetes who are at greater risk of developing the disease. Those at risk can participate in studies offering close monitoring or prevention trials testing interventions designed to interrupt the disease process.

Dr. Greenbaum is internationally recognized as a leader in translating basic science into clinical trials to prevent or intervene with the diabetes autoimmune process. She is well known as an expert in designing research protocols for individuals with type 1 diabetes. Type 1 diabetes is a growing medical problem, profoundly impacting children and adults with disease and their families, and Dr. Greenbaum’s work has had major impact in testing new approaches for early diagnosis and therapy.